Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
STRO-006 · 1 trial · 8 indications
| Arm | Type | Description |
|---|---|---|
| Part 1A STRO-006 monotherapy | EXPERIMENTAL | - |
| Part 1B STRO-006 monotherapy | EXPERIMENTAL | - |
| Part 1C STRO-006 in combination with pembrolizumab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| STRO-006 | DRUG | IV infusion |
| Pembrolizumab | DRUG | IV infusion |
Inclusion Criteria: * Histologically or cytologically documented refractory solid tumors that are recurrent or metastatic including: HNSCC (excluding EBV-positive nasopharyngeal carcinoma), NSCLC, esophageal/gastric cancer, colorectal cancer, endometrial carcinoma, urothelial carcinoma, and breast ...
STRO-006 is an investigational small molecule oncology drug developed by Sutro Biopharma, Inc. It is being studied in adults with refractory solid tumors that are recurrent or metastatic, including head and neck squamous cell carcinoma. It is in Phase 1 clinical development and has not been established as an approved therapy.
STRO-006 targets ITGB6, an integrin. ITGB6 belongs to the integrin class of cell surface receptors, and STRO-006 is a small molecule directed at this target. The Phase 1 program is evaluating the drug in refractory solid tumors, including head and neck squamous cell carcinoma.
STRO-006 is being evaluated in head and neck squamous cell carcinoma as part of a Phase 1 study in adults with refractory solid tumors that are recurrent or metastatic. The trial also enrolls patients with several other advanced solid tumor types. STRO-006 remains investigational and is not an approved treatment.
STRO-006 is developed by Sutro Biopharma, Inc., which trades under the ticker STRO. The company is running the Phase 1 clinical program for the small molecule in refractory solid tumors, including head and neck squamous cell carcinoma and other advanced cancers.
STRO-006 is in Phase 1 clinical development. Its single active trial is a Phase 1 study in adults with refractory solid tumors that are recurrent or metastatic. STRO-006 is investigational, and no completed trials of the drug are recorded.
STRO-006 is being studied in the Phase 1 trial NCT07807345, titled a Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic. The trial is recruiting in the United States with planned enrollment of 285 participants and includes head and neck squamous cell carcinoma among its conditions.